A new study from the UK’s National Health Service (NHS) into the symptoms of Omikron variant coronavirus infections confirms previous studies. Compared to the Delta variant, Omikron causes a sore throat much more often, but only a fraction as often as loss of smell and taste.
That the Omikron-variant the corona pandemic has changed for good is an understatement. This latest variant appears to be much more contagious and has pushed the infection rates to record highs in almost all countries. Nevertheless, the Omikron variant was also good news in many respects. This new variation appears to have resulted in relatively fewer hospital admissions, especially among those who have been vaccinated against the corona virus.
British, Japanese and Indian researchers have already discovered that changes to the spine protein of the virus have reduced the ability of the Omikron variant to penetrate and develop into the lung cells. The virus, on the other hand, would develop much more in the bronchi, the airways under the windpipe. Not only does this reduce the severity of cases, but it is also the reason why Omikron is more contagious.
Sore throat more often
A new, recent study by the NHS It has once again been shown that Omikron has a very different effect on the human body than the previous large variant, namely Delta. This difference is certainly reflected in the symptoms that infected people experience.
The most characteristic difference in symptoms is the occurrence of sore throat. Compared to the Delta variant, people infected with the Omikron variant would suffer from sore throats almost twice as often. Fever and cough are also more common, 16 and 13 percent more, respectively, compared to Delta.
Much less loss of smell and taste
What people infected with Omikron suffer from much less often is a loss of smell and taste. Compared to Delta infections, that would be barely one-fifth as common. Red and irritated eyes are 30 percent less common and also sneezing (-19 percent), a runny nose (-18 percent), shortness of breath (-16 percent), loss of appetite (-15 percent), headache (-9 percent) and dizziness (-9 percent) is less commonly diagnosed.
–
